page_title: KP1019
section_title: Mechanism of action
hierarchical_section_title: KP1019 / Mechanism of action
caption_attribution_description: English: Human Transferrin (Tf) PDB: 2HAU
context_page_description: KP1019, or trans-[tetrachlorobisruthenate(III)], is one of two ruthenium anti-cancer drugs to enter into phase I clinical trials, the other being NAMI-A. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer.
caption: Human Transferrin (Tf) PDB: 2HAU
exif: {"Image Artist": "Patricia Tolbert", "Image ExifOffset": "2140", "Image XPAuthor": "Patricia Tolbert", "Image Padding": "[]", "EXIF DateTimeOriginal": "2016:04:18 18:56:50", "EXIF DateTimeDigitized": "2016:04:18 18:56:50", "EXIF SubSecTimeOriginal": "37", "EXIF SubSecTimeDigitized": "37", "EXIF Padding": "[]"}